George Mason University and Rutgers Cancer Institute of New Jersey
Name Theralink Technologies as the Commercial Provider of Critical Assay
DENVER – February 22, 2021 – In a recent announcement by Rutgers Cancer Institute of New
Jersey and the Center for Applied Proteomics and Molecular Medicine at George Mason
University (CAPMM), Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”),
was named commercial provider of its patented Reverse Phase Protein Array (RPPA)
technology for breast cancer patients, if the proposed study has a positive outcome.
George Mason and Rutgers’ collaboration recently received the U.S. Army’s prestigious Breast
Cancer Research Program (BCRP) Breakthrough Award. From here, the project’s overall goal
is clinical validation – equating to a new way for measuring HER2+ breast cancer based
on the tumor’s activation (phosphorylation) state. Further, the measurement in the form of
the Theralink® assay, may be predictive, by using only the patient’s diagnostic biopsy, to
determine whether or not that patient will respond favorably to the treatment.
“This is a massive step forward, further validating what has been previously proven through
the nationally recognized ISPY2 trials– that Theralink’s patented RPPA technology might
mean a change in the Standard of Care for all women newly diagnosed with HER2+ breast
cancer,” said Mick Ruxin, M.D., President & CEO of Theralink Technologies. “This cohort of
patients accounts for approximately 25 percent of all US women’s breast cancer or upwards of
70,000 patients annually. It may be a game changer in the world of oncology and may make a
meaningful impact on so many cancer patients.”
Theralink’s RPPA testing measures the direct activation state for dozens of drug targets at
once. This can potentially provide oncologists with key information about the patient’s specific
tumor and possible clinical pathways.
“We’ve partnered with Theralink who will be responsible for the assay commercialization and
expanded clinical assessment to provide possible accelerated adoption and clinical use by
medical oncologists,” said Emanuel Petricoin, CAPMM co-director, and a scientific advisor to
the Company. “We have set up the infrastructure to quickly deploy the information and
technology; if this holds true, we have a commercial partner ready to take it to the bedside as
part of a patient clinical care plan and treatment decision support tool.”
“The rigorous blinded validation of the new test with our Rutgers colleagues will be the first
step toward potentially realizing an important clinical impact for breast cancer,” said Lance A.
Liotta M.D. PhD, Co-Director Center for Applied Proteomics and Molecular Medicine, Medical
Director Clinical Proteomics Lab College of Science, George Mason University.
For more clinical information on the George Mason University and Rutgers Cancer Institute of
New Jersey collaboration, visit science.gmu.edu.
About Theralink Technologies, Inc.
Theralink Technologies is a proteomics-based, molecular profiling and precision medicine
company with a CLIA-certified laboratory located in Golden, Colorado. Through its unique and
patented phosphoprotein and protein biomarker platform and LDTs, Theralink’s technology
targets multiple areas of oncology and drug development. Theralink provides precision
oncology data through its powerful Theralink® Reverse Phase Protein Array assays to assist
the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-
responders to both FDA-approved and investigational drug treatments. Theralink intends to
help improve cancer outcomes for patients, reveal therapeutic options for oncologists, and
support biopharmaceutical drug development by using a beyond-genomics approach to
molecular profiling that directly measures drug target levels and activity. For more information,
please visit www.theralink.com.
The Firm Public Relations & Marketing
Jasen Woehrle and Jesse Scott
Certain statements contained in this press release are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation,
anything relating or referring to future financial results, patient enrollment and plans for future
business development activities, and are thus prospective. Forward-looking statements are
inherently subject to risks and uncertainties some of which cannot be predicted or quantified
based on current expectations. Such risks and uncertainties include, without limitation, the risks
and uncertainties set forth from time to time in reports filed by Theralink Technologies with the
Securities and Exchange Commission. We have based these forward-looking statements
largely on our current expectations and projections about future events and financial trends
affecting the financial condition of our business and although the company believes that the
expectations reflected in such forward-looking statements are reasonable, it can give no
assurance that such expectations will prove to have been correct. Consequently, future events
and actual results could differ materially from those set forth in, contemplated by, or underlying
the forward the forward-looking statements contained herein. The company undertakes no
obligation to publicly release statements made to reflect events or circumstances after the date